News | Artificial Intelligence | January 22, 2020

Oxipit Partners with HealthCare Konnect to Bring AI Diagnostics to Africa

The partnership aims to introduce vanguard AI diagnostic capabilities and improve detection of 75 pathologies

Medical imaging technology company Oxipit announced partnership with Swiss medical distribution company Healthcare Konnect to bring ChestEye AI imaging suite to healthcare institutions in Nigeria

January 22, 2020 — Medical imaging technology company Oxipit announced partnership with Swiss medical distribution company Healthcare Konnect to bring ChestEye AI imaging suite to healthcare institutions in Nigeria. The partnership aims to introduce vanguard AI diagnostic capabilities and improve detection of 75 pathologies, including tuberculosis, to one of the largest markets in Africa.

With over 200 million, Nigeria is the most populated country in Africa. Although in decline, tuberculosis still accounts for a disproportionate amount of deaths due to lack of timely and effective diagnosis, despite treatments for the disease being available. The Association of Radiologists of Nigeria (ARIN) has expressed concern over the shortage of radiologists with only 400 radiology specialists estimated for the entire population. 

"We are eager to support radiologists in improving diagnostics in both rural and heavily populated regions of Africa,” said Marwan Senhaji, managing director of HealthCare Konnect. “Oxipit ChestEye imaging suite will aid radiologists in their diagnostics workflow, reduce time per patient and will be beneficial in training of radiology specialists” added Nataniel Herzog, senior project manager for Nigeria. 

Oxipit ChestEye imaging suite encompasses a fully automatic computer aided diagnosis (CAD) platform which supports 75 radiological findings. The software generates a standardized preliminary text report that incorporates all the radiologically relevant information present in a chest X-ray image. ChestEye imaging suite also features a patient prioritization solution. By automatically arranging scans by urgency it reduces time-to-treatment for time sensitive conditions.

“We are excited to introduce AI capabilities of our imaging suite in Nigeria, where improvements in diagnostics can bring significant benefits for patient care. The productivity features of ChestEye imaging suite can lead to 30% time saved per patient and reduction in error-rate of up to 50%. In addition, the platform is instrumental in radiology resident training,” noted CEO of Oxipit Gediminas Peksys

Oxipit ChestEye was created to address the shortage of radiologist in developed and developing markets. In February ChestEye imaging suite received CE mark certification. Oxipit expertise in deep learning allows to adapt ChestEye imaging suite for diverse clinical settings. 

Recently Oxipit introduced AI X-ray longitudinal comparison. The dynamics enables a radiologist to compare X-rays and provide automatically generated reports specifically addressing the changes in images over the course of patient treatment. Oxipit is also developing ChestEye Quality - an automated clinical audit service for retrospective X-ray report analysis, and ChestEye Negative - a service to produce preliminary reports for chest X-ray images with no abnormality.

For more information: www.oxpit.ai

Related content:

A Glimpse Into Radiology in the Developing World in Africa

Oxipit Introduces Multilingual Support for ChestEye AI Imaging Suite

Oxipit to Showcase AI X-ray Longitudinal Comparison at RSNA

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Getty Images

Feature | Coronavirus (COVID-19) | April 03, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal.

An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal. Photo by Dave Fornell

Feature | Radiology Imaging | April 02, 2020 | By Katie Caron
A new year — and decade — offers the opportunity to reflect on the advancements and challenges of years gone by and p
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus

Getty Images

Feature | Coronavirus (COVID-19) | April 02, 2020 | Jilan Liu and HIMSS Greater China Team
Information technologies have played a pivotal role in China’s response to the novel coronavirus...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 the company is now offering a suite of AI solutions Vuno Med-LungQuant and Vuno Med-Chest X-ray for COVID-19, encompassing both lung X-ray and computed tomography (CT) modalities respectively all at once
News | Artificial Intelligence | April 02, 2020
April 2, 2020 — In the face of the COVID-19 pand
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 A brief article from Henry Ford Health System in Detroit, published today in Radiology, reports on the first presumptive case of COVID-19–associated acute necrotizing hemorrhagic encephalopathy.

A, Image from noncontrast head CT demonstrates symmetric hypoattenuation within the bilateral medial thalami (arrows). B, Axial CT venogram demonstrates patency of the cerebral venous vasculature, including the internal cerebral veins (arrows). C, Coronal reformat of aCT angiogram demonstrates normal appearance of the basilar artery and proximal posterior cerebral arteries. Image courtesy of the Radiological Society of North America (RSNA)

News | Coronavirus (COVID-19) | March 31, 2020
March 31, 2020 — A brief article fr
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 The Chinese start-up company Infervision launches its AI-based solution InferRead CT Lung Covid-19 also in Europe
News | Artificial Intelligence | March 31, 2020
March 31, 2020 — Lung infections generated by the coronavirus can be detected in...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Doctor in our hospital is using this intelligent system for accurate diagnosis

Doctor in our hospital is using this intelligent system for accurate diagnosis. (Photo: Business Wire)

News | Artificial Intelligence | March 31, 2020
March 31, 2020 — The Intelligent Evalua...